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A major goal in developing protective immune 
responses is to obtain robust CD8 T cell ex-
pansion, effector differentiation, and memory 
generation using simple protein antigens as 
immunogens. We have previously reported that 
IL-1 strikingly enhances CD4 T cell responses 
when administered to mice during the period 
immediately after priming (Ben-Sasson et al., 
2009), and thus wished to determine whether 
it would have a comparable effect on CD8 cells.
IL-1’s effect on CD4 T cells was observed 
in vivo, was direct, and largely reflected en-
hanced survival rather than increased prolif-
erative rate. Furthermore, when wild-type and 
IL1R1/ CD4 TCR transgenic T cells specific 
for an OVA peptide were jointly transferred to 
IL1R1/ recipients, only the wild-type cells 
responded to IL-1 with enhanced antigen-
driven expansion (Ben-Sasson et al., 2009). This 
result indicates that IL-1 acts directly on the 
antigen-responding CD4 cell. Of a wide range 
of cytokines, including IL-2, -4, -6, -7, -9, -15, 
-18, -21, and -33, as well as TNF, only IL-1 
and IL-1 showed such profound enhance-
ment activity (Ben-Sasson et al., 2009). The IL-1 
effect was observed in both IL-6– and in CD28-
deficient recipients. Neutralizing IL-1 diminished 
responses to protein plus LPS by 60%, imply-
ing that endogenous IL-1 enhanced antigen-
specific CD4 T cells responses.
IL-1 strikingly enhanced antigen-driven ex-
pansion in vivo and enhances in vitro expan-
sion of Th17 cells, which express large amounts 
of IL-1R1 (Guo et al., 2009; Lee et al., 2010), 
but it had no detectable effect on in vitro ex-
pansion of Th1 or Th2 cells. However, adminis-
tering IL-1 in vivo during CD4 T cell priming, 
while increasing the proportion of Th17 cells 
among responders, also causes striking expan-
sion of both IFN- and IL-4–producing cells 
(Ben-Sasson et al., 2009).
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Here, we show that interleukin-1 (IL-1) enhances antigen-driven CD8 T cell responses. 
When administered to recipients of OT-I T cell receptor transgenic CD8 T cells specific for 
an ovalbumin (OVA) peptide, IL-1 results in an increase in the numbers of wild-type but 
not IL1R1/ OT-I cells, particularly in spleen, liver, and lung, upon immunization with OVA 
and lipopolysaccharide. IL-1 administration also results in an enhancement in the frequency 
of antigen-specific cells that are granzyme B+, have cytotoxic activity, and/ or produce 
interferon  (IFN-). Cells primed in the presence of IL-1 display enhanced expression of 
granzyme B and increased capacity to produce IFN- when rechallenged 2 mo after prim-
ing. In three in vivo models, IL-1 enhances the protective value of weak immunogens. Thus, 
IL-1 has a marked enhancing effect on antigen-specific CD8 T cell expansion, differentia-
tion, migration to the periphery, and memory.
This article is distributed under the terms of an Attribution–Noncommercial–Share 
Alike–No Mirror Sites license for the first six months after the publication date 
(see http://www.rupress.org/terms). After six months it is available under a Cre-
ative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported 
license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).
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They did or did not receive IL-1 for 5 d (2 µg/day) beginning 
24 h after immunization. IL-1 administration caused a strik-
ing increase in the frequency of transgenic cells at 7 d after 
immunization (Fig. 1 A). In 9 consecutive experiments, the 
increase caused by IL-1 in OT-I cell numbers 7 d after im-
munization was 20.5-fold in the lymph node and 63.6 in the 
spleen (Fig. 1 B). When CD45.1 OT-I cells were transferred 
into wild-type or IL-1R1/ CD45.2 recipients, the degree 
of IL-1–mediated enhancement of antigen-driven expansion 
was similar in the two sets of recipients in both lymph nodes 
and spleens (Fig. 1 C), implying that the bulk of the IL-1– 
mediated enhancement of antigen-stimulated CD8 T cell prim-
ing required the expression of the IL-1 receptor on the 
antigen-responding CD8 T cells and that IL-1 receptor ex-
pression on other cells played only a limited role in enhanced 
expansion in lymph node and spleen.
IL-1–mediated enhancement of OT-I expansion  
does not require CD4 T cells
OT-I cells were transferred into Rag1/ B6 recipients. 9 d later, 
mice were immunized with OVA plus LPS with or without 
IL-1. In unimmunized mice, IL-1 alone caused no enhance-
ment in OT-I number. The administration of IL-1 to mice 
treated with OVA plus LPS caused a substantial increase in 
frequency of OT-I cells in lymph node and spleen, indicating 
that in the total absence of CD4 T cells, IL-1 could enhance 
antigen-driven OT-I expansion (Fig. 2 A). When OT-I cells 
were transferred to IL-1R1/ B6 recipients, the IL-1–mediated 
increase in their response to OVA plus LPS was not enhanced 
by the co-transfer of a similar number of CD4 OT-II cells 
(Fig. 2 B). Thus, IL-1 enhancement of antigen-driven expan-
sion of CD8 T cells 1 wk after immunization does not depend 
upon “help” from CD4 T cells. It should be noted that in both 
models, the response of OT-I cells to OVA plus LPS, without 
IL-1, was also not enhanced by the presence of CD4 T cells.
IL-1 causes a massive increase in the frequency  
of OT-I cells in liver and lung in response to immunization
OT-I cells were transferred into UBC-GFP recipients; the 
mice were immunized with OVA plus LPS with or without 
IL-1. At 7 d after immunization (Fig. 3 A), a low frequency of 
OT-I cells were found in the lymphocyte-enriched fractions 
of lung (0.7%) and liver (4.7%). The addition of IL-1 caused 
a massive increase in the frequency of OT-I cells in both or-
gans. Indeed, OT-I cells were now the great majority of total 
CD8 cells and made up 56% of all cells in the lymphocyte-
enriched fractions in liver and 27% in lung.
IL-1 also resulted in an increase in the total number of 
cells in the liver and lung lymphocyte-enriched Percoll bands 
(unpublished data). Taking into account the increase in the 
percentage of OT-I cells and the increase in total cells in the 
lymphocyte-enriched fraction, the absolute numbers of OT-I 
cells in the liver increased by 68-fold; in the lung, the increase 
was 118-fold (Fig. 3 B).
As already noted, the IL-1–mediated increase in num-
bers of responding OT-I cells in lymph node and spleen was 
The role of IL-1 in regulating CD8 T cell responses has 
not been clear. Some have reported that IL-1 enhances in vitro 
expansion of CD8 cells responding to polyclonal stimulants 
(Mizuochi et al., 1988; Hope et al., 2001). Where studied, it 
appears that the in vitro effects of IL-1 have been limited to 
cells expressing large amounts of IL-1R1 (Klarnet et al., 1989; 
Nagoya et al., 1994). In one instance, enhanced capacity to 
produce IFN- was observed (Fischer et al., 1990). How-
ever, others have failed to observe IL-1–mediated enhancement 
of in vitro TCR-driven CD8 T cell expansion (Halvorsen 
et al., 1987; Panzer et al., 1990; Curtsinger et al., 1999).
IL1R1/ mice have been reported to have diminished 
CD8 responses to infection with LCMV (Joeckel et al., 2012), 
influenza (Ichinohe et al., 2009), Mycobacterium tuberculosis 
(Fremond et al., 2007), vaccinia (Staib et al., 2005), and cer-
tain tumors (Elkabets et al., 2009; Ghiringhelli et al., 2009). 
In addition, Myd88/ and/or IRAK-4/ mice, both of 
which have defective IL-1–mediated signaling, have impaired 
responses to LCMV (Lye et al., 2008), vaccinia (Zhao et al., 
2009), and malaria (Gowda et al., 2012). CD8 T cells specific 
for LCMV appearing in infected IL1R1/ mice were re-
ported not to express granzyme B (Joeckel et al., 2012). Fur-
thermore, vaccinia that fail to display a virally encoded soluble 
IL-1 receptor elicit greater protection and improved CD8 
memory responses (Staib et al., 2005) implying that neutral-
izing endogenous IL-1 normally limits immunity to vaccinia. 
However, in these infection models, the cell target of IL-1 was 
not established.
We sought to determine the importance of IL-1 in in vivo 
priming and differentiation of antigen-specific CD8 T cells. 
To that end, we transferred WT OT-I cells to WT or IL1R1/ 
C57BL/6 recipients that were then immunized with OVA 
plus LPS. IL-1R1/ recipients showed increases of WT OT-I T 
cells comparable to WT recipients in response to IL-1 in 
lymph nodes and spleen, but not in liver and lung. IL-1 ad-
ministration also resulted in a striking enhancement in the 
frequency of granzyme B+ cells, in cytotoxic activity, and in 
cells that produced IFN- in response to PMA and ionomycin. 
Mice primed in the presence of IL-1 developed secondary 
CD8 T cells responses marked by enhanced expression of 
granzyme B and augmented capacity to produce IFN- when 
rechallenged 2 mo after priming. In three in vivo models, 
IL-1 enhanced the protective value of weak immunogens. 
Thus, IL-1 has a striking effect on enhancing antigen-specific 
CD8 T cell expansion, differentiation, migration to the pe-
riphery, and memory.
RESULTS
IL-1 acts on CD8 T cells to enhance  
antigen-driven expansion
To test the effect of IL-1 on antigen-driven expansion of 
CD8 T cells, we transferred 104 lymph node cells from B6 
OT-I TCR transgenic Rag1/ donors to C57BL/6 mice 
that express GFP under the direction of the ubiquitin C pro-
moter (UBC-GFP mice). The recipients were immunized 
subcutaneously with 1 mg OVA together with 25 µg LPS. 
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IL-1 enhances effector function of CD8 T cells  
in response to antigen stimulation
Immunization of mice that received OT-I cells alone or 
OT-I cells plus OT-II cells with OVA plus LPS caused rela-
tively few cells to express granzyme B or to produce IFN- 
when stimulated with PMA plus ionomycin. Addition of 
IL-1 caused a striking increase in the proportion of granzyme 
B–expressing cells and in the fraction of OT-I cells that pro-
duced IFN- in response to stimulation (Fig. 4 A).  In spleen, 
and particularly in liver and lung, the addition of IL-1 strik-
ingly increases the proportion of granzyme B and of IFN-–
producing cells and the MFI of both granzyme B and IFN- 
staining (Fig. 4, B and C). Strikingly, the increase in both 
granzyme B expression and in the proportion of IFN-–pro-
ducing cells did not occur if the recipients were IL-1R1/ 
mice (Fig. 4 D). Thus, the enhanced “differentiation” of the 
responding cells was a complex process presumably requiring 
both a direct interaction of IL-1 with the responding T cells 
for their expansion and possibly their differentiation and a 
independent of IL-1R1 expression in the non–OT-I cells. In 
Fig. 3 D, we show that there are actually more OT-I cells in 
lymph nodes and spleen of immunized IL1R1/ recipients 
treated with IL-1 than in WT recipients, although the differ-
ence is not statistically significant. In contrast, the number of 
OT-I cells in liver and lung of immunized IL-1R1/ recipi-
ents treated with IL-1 is far less than in similarly treated WT 
recipients. In this experiment, recipients received both OT-I 
and OT-II cells.
Entry into liver and lung was also diminished in IL1R1/ 
OT-I–recipient mice that were immunized with OVA plus 
LPS without exogenous IL-1 (Fig. 3 C). These results indi-
cate that entry or retention in liver and lung requires IL-1R1 
expression in cells other than the antigen-specific T cells, 
presumably at the local site of accumulation, whether IL-1 is 
administered or not, implying that IL-1, whether endoge-
nous or administered, plays a central role in migration into 
nonlymphoid organs of recently primed effector or effector/
memory CD8 T cells.
Figure 1. IL-1 enhances antigen-driven 
CD8 T cell responses. (A) 104 OT-I cells were 
injected into UBC-GFP C57BL/6 mice. Mice 
were immunized subcutaneously with LPS 
with or without IL-1. 7 d after priming, the 
frequency of splenic GFP CD8+ OT-I cells was 
determined. Results are presented as the per-
centage of cells in total splenic lymphocytes. 
(B) 1–3 × 104 OT-I cells were injected into 
UBC-GFP, CD45.1, or CD90.1 C57BL/6 mice. 
Mice were immunized with OVA plus LPS with 
or without IL-1. 7 d after priming, the per-
centage and total number of transferred OT-I 
cells in the organs was determined. Data are 
the mean ratios of the number of OT-I cells in 
mice immunized with OVA plus LPS plus IL-1 
compared with that in mice immunized with 
OVA plus LPS from nine experiments. (C) 104 
CD45.1 OT-I and 104 CD45.1 OT-II cells were 
injected into CD45.2 IL-1R1/ and wild-type 
CD45.2 C57BL/6 mice. Mice were immunized 
with OVA plus LPS with or without IL-1. 7 d 
after priming, cells were analyzed for number 
of OT-I cells. This experiment was performed 
three times with similar results.
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We also immunized normal B6 mice with OVA plus LPS 
with or without IL-1. The addition of IL-1 increased the fre-
quency of CD8 T cells that bound a SIINFEKL tetramer 
(Fig. 5 B) in both lymph node and spleen, indicating that IL-1 
is active on conventional CD8 T cells as well as on transgenic 
cells. Although mice immunized with OVA plus LPS displayed 
very limited cytotoxic activity for SIINFEKL-sensitized cells 
as determined by injection of mixture of sensitized and non-
sensitized target cells into these animals, those that had received 
IL-1 in the immunization protocol showed striking cytotoxic 
activity in both lymph nodes and spleen (Fig. 5 C).
Mice primed with OVA, LPS, and IL-1  
show striking secondary responses
Mice that had received OT-I cells were immunized with 
OVA and LPS with or without IL-1. 8 wk later, these mice 
were challenged subcutaneously with OVA plus LPS, without 
IL-1. 3 d after the boost, there was a trend for more OT-I cells 
in lymph node, spleen, liver, and lung in mice that had been 
originally primed in the presence of IL-1 (Fig. 6, A and B). 
The IL-1–primed cells from each organ showed high fre-
quencies of granzyme B+ cells and cells that produced IFN- 
in response to PMA and ionomycin, whereas cells from these 
organs derived from mice primed without IL-1 showed sub-
stantially less granzyme B or IFN- (Fig. 6 C). The relatively 
high proportion of IFN- producers in the lung of mice that 
contribution of IL-1–stimulated recipient cell function for 
expression of granzyme B and production of IFN-.
Inclusion of IL-1 in the immunization protocol also in-
creases the cytotoxic activity of primed CD8 T cells. We im-
munized OT-I transgenic mice with OVA plus LPS with or 
without IL-1. 9 d after priming, we transferred graded num-
bers of OT-I cells from the primed donors to naive B6 recipi-
ents. We then tested cytotoxic activity of the transferred cells 
by injecting a mixture of B6 splenocytes labeled with a high 
concentration of CFSE and loaded with SIINFEKL and of 
control cells labeled with a low concentration of CFSE. We 
measured the relative numbers of CFSEhigh and CFSElow cells 
18 h later in lymph node cell suspensions. Transfer of 7.2 × 
105 cells from either donor resulted in a striking depletion of 
SIINFEKL-loaded cells (Fig. 5 A), indicative of cytotoxic ac-
tivity.  In contrast, when 1.2 × 105 OT-I cells were transferred, 
only those from the donor that had been immunized with 
IL-1 displayed cytotoxic activity. Transfer of 0.2 × 105 cells 
from donors primed in the presence of IL-1 resulted in sig-
nificant but diminished cytotoxic activity, whereas cells from 
donors immunized with OVA plus LPS showed no cytotoxic 
activity. In both the 1.2 × 105 and the 0.2 × 105 groups, the 
differences in the presence and absence of IL-1 were statisti-
cally significant. Thus, on a per cell basis, immunization with 
IL-1 resulted in a greater than sixfold increase in their in vivo 
cytotoxic activity.
Figure 2. IL-1 enhancement of CD8 responses does 
not depend on CD4 cells. (A) 4 × 105 OT-I cells were  
injected into Rag1/ C57BL/6 mice. Mice were immunized 
with OVA and LPS with or without IL-1. 7 d after priming, 
the number of transferred OT-I cells was determined. This 
experiment was performed twice with similar results. 
(B) 3 × 104 OT-I cells with or without 3 × 104 OT-II cells 
were injected into IL-1R1/ C57BL/6 mice that were immu-
nized with OVA, LPS with or without IL-1. 7 d after priming, 
the number of OT-I cells was measured. This experiment was 
performed twice with similar results.
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IL-1 enhances protectivity of weak or ineffective vaccines
We wished to determine whether the striking IL-1–mediated 
enhancement in both CD4 and CD8 T cell expansion and 
the accompanying increase in effector phenotype would 
allow greater efficacy of weak vaccines if IL-1 was included in 
the vaccination protocol. We chose three model systems for 
analysis, heat-killed Listeria monocytogenes (HKLM) as a vac-
cine for challenge with live L. monocytogenes, an HIV peptide 
as a vaccine for recombinant vaccinia, a human papilloma 
virus (HPV)–derived peptide as a therapeutic vaccine for TC1 
HPV-transformed lung epithelial cells.
had not been immunized with IL-1 may reflect the difficulty 
in phenotyping the very small number of such cells in the 
lung. An example of the difference in liver and lung between 
mice primed with or without IL-1 is shown in Fig. 6 A. In the 
IL-1–primed groups, the majority of spleen, liver, and lung 
OT-I cells were granzyme B+, and the frequency of IFN- 
producers in these organs was 40% (Fig. 6 C). Thus, the 
striking phenotypic properties of OT-I cells observed 7 d after 
priming with IL-1 were also observed when these mice were 
boosted 8 wk later, even though IL-1 was not administered in 
the booster immunization.
Figure 3. IL-1 increases the frequency of 
OT-I cells in liver and lung. (A) 104 OT-I 
cells were injected into UBC-GFP C57BL/6 
mice. Mice were immunized with OVA and  
LPS with or without IL-1. 7 d after priming, 
lymphocyte-enriched fractions were isolated 
from liver and lung and cells were analyzed 
for proportion of OT-I cells. This experiment 
was performed six times with similar results.  
(B) 104 OT-I cells were injected into UBC-GFP 
C57BL/6 mice that were then immunized with 
OVA and LPS with or without IL-1. 7 d after 
priming, lymphocyte-enriched fractions were 
isolated from liver and lung and number of 
OT-I cells was measured. This experiment was 
performed four times with similar results. 
(C) 1–3 × 104 OT-I cells were injected into 
UBC-GFP CD45.1, CD90.1 C57BL/6, CD45.1 
C57BL/6, or IL-1R1/ C57BL/6 mice. Recipi-
ents were immunized with OVA plus LPS. 7 d 
later, the percentage of transferred OT-I cells 
among the CD8 population in lymph nodes, 
spleen, liver, and lung was determined. The 
mean ratio of the percentage of OT-I in CD8 
in liver, lung, and spleen compared with that 
of the lymph nodes from five experiments in 
WT mice (red) and from three experiments in 
IL-1R1/ recipients (green) were calculated. 
In addition, in one experiment (blue), 106 OT-I 
cells were transferred without immunization 
and the ratio of the percentage of OT-I in CD8 
in liver, lung, and spleen compared with that 
of the lymph nodes was determined. (D) 104 
CD45.1 OT-I and 104 CD45.1 OT-II cells were 
injected into CD45.2 IL-1R1/ and wild-type 
C57BL/6 mice. Mice were immunized with 
OVA and LPS with or without IL-1. 7 d after 
priming, single-cell suspensions from the 
lymph nodes, spleen, liver, and lung were 
analyzed by FACS for the content of OT-I cells. 
The ratio of the number of OT-I cells in the 
presence of IL-1 to that in its absence is  
plotted. This experiment was performed  
twice with similar results.
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Figure 4. IL-1 enhances CD8 T cell differentiation. (A) 104 OT-I and 104 OT-II cells were injected into UBC-GFP C57BL/6 mice. Mice were immu-
nized with OVA and LPS with or without IL-1. 7 d after priming, cells from the lymph nodes, spleen, liver, and lung were stimulated for 4 h with PMA 
and ionomycin, and the percentage of granzyme B+ cells and IFN-+ cells among the OT-I cells was determined. This experiment was performed four 
times with similar results. (B) 104 OT-I and 104 OT-II cells were injected into UBC-GFP C57BL/6 mice. 6 d later, the mice were immunized with OVA and 
LPS with or without IL-1. 7 d after priming, cells from the lymph nodes, spleen, liver, and lung were stimulated for 4 h with PMA and ionomycin. The 
percentage of granzyme B+ cells and IFN-+ cells among the CD8+ GFP OT-I cells in the various organs was determined. This experiment was per-
formed five times with similar results. (C) The MFI of granzyme B and IFN- among positive cells in the various organs was determined by FACS analysis. 
This experiment was performed four times with similar results. (D) 104 CD45.1 OT-I and 104 CD45.1 OT-II cells were injected into CD45.2 IL-1R1/ 
C57BL/6 mice. Mice were immunized with OVA and LPS with or without IL-1. 7 d after immunization, cells from the lymph nodes, spleen, liver, and 
lung were stimulated for 4 h with PMA and ionomycin. The percentage of granzyme B+ cells and IFN-+ cells among the OT-I cells was measured. 
There were no statistically significant differences in values obtained in mice that did and did not receive IL-1. This experiment was performed twice 
with similar results.
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Fig. 7 A shows that unvaccinated mice infected with 4 × 
104 live L. monocytogenes display 5.85 log10 CFU of bacteria in 
the liver 3 d after challenge. If they had been immunized 
with 500 live L. monocytogenes 30 d earlier, they had 2.6 log10 
fewer CFU. Immunization with 500 HKLM provided no 
benefit, but the addition of IL-1 to HKLM immunization 
protocol yielded a 2.0 log10 reduction in liver CFU com-
pared with unimmunized mice. We repeated this experiment 
using 50,000 HKLM as the immunogen with or without 
IL-1 and again observed no protection in the HKLM group 
and significant protection in the group that received HKLM 
and IL-1 (unpublished data). In a separate experiment, we 
measured survival of mice infected with live Listeria. All mice 
that were unimmunized, received 50,000 HKLM alone or 
IL-1 alone had either died by day 4 or had to be euthanized 
because of excessive weight loss. In contrast, three of five 
mice that received HKLM plus IL-1 survived as did all 
the mice that had been immunized with live Listeria (data 
not shown).
Challenging BALB/c mice with 2 × 107 PFU of recom-
binant vaccinia virus expressing HIV gp160IIIB resulted in 
7.3 × 107 PFU in the ovaries 6 d after infection. Immuniza-
tion with peptide containing the immunodominant CTL 
epitope of the vaccinia-expressed gp160IIIB HIV protein 
(Takahashi et al. 1988; Takeshita et al., 1995) 7 d earlier re-
sulted in a modest degree of protection, to 4.0 × 107 PFU. 
Including TLR ligands (MALP2, poly[I:C], and CpG ODN 
1555 and 1466; Zhu et al., 2010) in the immunization proto-
col resulted in 8.5 × 106 PFU upon challenge. Using IL-1 
rather than the TLR ligand mixture provided greater protec-
tion, reducing the PFU to 4.0 × 106, a statistically significant 
improvement over the TLR ligand mixture (Fig. 7 B).
5.0 × 104 HPV-transformed lung epithelial TC1 cells 
were injected into the right flank of C57BL/6 mice. 14 d 
later, when the tumor could be palpated, the animals were 
either not immunized or immunized with 100 µg HPV E749-57 
peptide plus 25 µg LPS or LPS + IL-1 (4 doses of 2 µg on day 0, 
1, 2, and 4 after immunization). Tumor sizes were measured 
until day 18 after immunization. The group immunized with 
IL-1 had statistically significantly smaller tumors from day 4 
onward (Fig. 7 C).
DISCUSSION
In this study, we have shown that the expansion of naive 
TCR transgenic CD8 T cells in response to immunization 
with their cognate antigen plus LPS is enhanced by >60-fold 
in the spleen and 20-fold in lymph nodes by administration 
of IL-1 over the 5 d after immunization. The effect of IL-1 
on CD8 T cell expansion in lymph node and spleen does not 
require that cells other than the CD8 T cells express IL-1R1. 
The IL-1 effect does not depend on the presence of CD4 
T cells although IL-1 does enhance the antigen-driven response 
of these cells (Ben-Sasson et al., 2009).
Although the mechanism of the IL-1–induced enhance-
ment in lymph node and spleen is not known, it is unlikely 
to be a result of an “overriding” of a possible inhibitory effect 
Figure 5. IL-1 increases cytotoxic activity in vivo. (A) OT-I mice 
were primed in vivo with OVA and LPS with or without IL-1 (3 daily s.c. 
injections on days 1, 3, and 5 after immunization). 9 d later, 7.6 × 105, 
1.2 × 105, or 0.2 × 105 cells from the immunized mice were transferred 
to C57BL/6 mice. 7 d after the OT-I transfer, recipient mice were in-
jected with 3 × 106 SIINFEKL-loaded CFSEhigh and 1.4 × 106 control  
CFSElow syngeneic splenocytes. 18 h later, lymph nodes were removed 
and the percentage of SIINFEKL-loaded cells among the CFSE-labeled 
population was determined. This experiment was performed twice with 
similar results. (B) C57BL/6 mice were immunized with OVA and LPS 
with or without IL-1. 8 d later, the percentage of SINFEKL tetramer-
binding cells among the CD8 population in the lymph nodes and spleen 
was determined. This experiment was performed three times with simi-
lar results. (C) C57BL/6 mice were immunized with OVA and LPS with or 
without IL-1. 7 d after priming, recipient mice were injected with 4 × 106 
SIINFEKL-loaded CFSEhigh and 2 × 106 control CFSElow syngeneic  
splenocytes. 18 h later, the percentage of SIINFEKL-loaded cells among 
the CFSE labeled population of lymph node and spleen was determined. 
This experiment was performed three times with similar results.
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majority of all the CD8 T cells in the organ. Interestingly, 
although the IL-1 effect on expansion in spleen and lymph 
node does not require IL-1R1 expression on cells other than 
the OT-I cells, this is not the case for cells trafficking to liver 
or lung. If the recipient is an IL-1R1–deficient mouse, OT-I 
cells fail to accumulate in liver or lung, implying that entry 
into, or retention in, these tissues is enhanced by the action of 
IL-1 on a tissue cell. Indeed, even the accumulation of OT-I 
cells in liver and lung in mice immunized with OVA plus LPS 
without exogenous IL-1 is diminished in IL1R1/ recipients. 
This implies that IL-1 action, possibly on vascular endothelial 
cells, is important to the robust entry of memory/effector or 
of regulatory T cells because only CD8 cells need to express 
IL-1R1 for the response to IL-1 to occur. For the same rea-
son, the principal effect is not on accessory cells, including 
DCs. A possible explanation for the IL-1–induced enhance-
ment in cell number is IL-1–mediated suppression of apoptosis 
in the antigen-stimulated CD8 cells (McConkey et al., 1990; 
McAleer et al., 2007; von Rossum et al., 2011), which ap-
pears to be the major mechanism for IL-1 enhancement of 
CD4 responses (Ben-Sasson et al., 2009).
The enhanced expansion of OT-I cells is particularly 
dramatic in the liver and lung where, even with transfer of 
10,000 cells, the responding OT-I cells constitute the great 
Figure 6. OT-I cells primed in the presence of IL-1 retain their phenotype upon boost 8 wk later. 104 OT-I and 104 OT-II cells were injected i.p. 
into UBC-GFP C57BL/6 mice. 6 d later, the mice were immunized with OVA and LPS with or without IL-1. 8 wk after priming, the mice were boosted with 
OVA and LPS. Three days later, cells from liver and lung were stimulated for 4 h with PMA and ionomycin. The percentage of granzyme B+ and IFN-+ 
cells among the OT-I cells in a representative animal is shown in A and summary cell number and percent of granzyme B+ and IFN-+ cells are shown in  
B and C. This experiment was performed three times with similar results.
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effector cells into liver and lung, and possibly other tissues, 
or to retention in these tissues. Indeed, IL-1 has been reported 
to regulate adhesion and/or transmigration of CD8 effec-
tor lymphocytes into various tissues by controlling chemo-
kine production and possibly adhesion molecule expression 
(Pietschmann et al., 1992; Sikorski et al., 1993; Wang et al., 
1993; Kanda et al., 1995; Freedman et al., 1996; Muehlhoefer 
et al., 2000; Stocker et al., 2000; Mohamadzadeh et al., 1998; 
Ding et al., 2000; McCandless et al., 2009).
Priming in the presence of IL-1 markedly induces gran-
zyme B expression, antigen-specific cytotoxic T cell activity, 
and IFN-–producing capacity of the antigen-specific re-
sponding CD8 T cells. What was quite interesting and some-
what perplexing was that the increased expression of granzyme B 
and the enhanced capacity to produce IFN- required ex-
pression of IL-1R1 by cells other than the responding CD8 
T cells. This implies that factors other than IL-1, possibly pro-
duced by dendritic cells that have received an IL-1 signal, are 
required to cooperate with those generated by IL-1 in the 
responding T cells to yield robust differentiation in the expand-
ing cells (Wesa and Galy, 2002; Sheng et al., 2008; Thompson 
et al., 2012).
Not only did recently primed cells display a greater de-
gree of differentiation when IL-1 was part of the immuniza-
tion regimen, CD8 cells from these mice showed greater 
granzyme B expression and IFN-–producing capacity when 
challenged 8 wk after priming without readministration of 
IL-1. Whether this secondary response reflects the expansion 
of highly differentiated cells in the tissues upon rechallenge 
or, more likely, the response of cells in spleen and/or lymph 
node followed by traffic to tissues immediately after the boost 
is still uncertain. In challenge with live influenza, the process 
of expansion of CD8 memory cells has been reported to occur 
largely in the secondary lymphoid organs, with the activated 
cells then migrating to the tissues (Kohlmeier et al., 2010).
The capacity of IL-1 to enhance both the expansion and 
differentiation of responding cells and the retention of the 
enhanced effector capacity of the differentiated cells upon 
boosting 8 wk late implies that IL-1 as an “adjuvant” could 
increase the “competence” of weak vaccines to provide pro-
tective activity. Indeed, we observed that IL-1 given together 
with HKLM resulted in a reduction by 2-log10 of the CFU 
titer in liver compared with immunization with HKLM alone 
even when the number of HKLM was very low. When IL-1 
was used with an HIV peptide, 1 log10 of increased protec-
tion was obtained against a recombinant vaccinia expressing 
the gp160IIIB HIV protein. IL-1 also enhanced the efficacy 
of a peptide vaccine against an established tumor. In unpub-
lished work, we have observed that IL-1 enhances the role of 
both subunit and attenuated Herpes simplex vaccines to offer 
protection (unpublished data) and increases the protection 
Figure 7. IL-1 effect on protective responses to L. monocytogenes, 
recombinant vaccinia, and a tumor line. (A) C57BL/6 mice were either 
untreated, inoculated with 500 live L. monocytogenes (Lm), the equiva-
lent of heat-killed L. monocytogenes (HKLM), or HKLM and IL-1 (10 µg 
delivered over 7 d in a mini-osmotic pump). 29 d later, the mice were 
challenged with 5 × 104 CFU of live Lm. Bacterial CFU in liver were enumer-
ated 3 d later. This experiment was performed three times with similar 
results. (B) BALB/c mice were immunized twice with 100 µg of the HIV-1 
peptide RGPGRAFVTI, 10 d apart, alone, with IL-1, or with a cocktail of  
TLR ligands, and then infected i.p. with 2 × 107 recombinant vaccinia virus 
(vPE16) 1 wk after the last immunization. 6 d after infection, viral load in 
the ovaries was determined by a plaque assay using BSC-1 cells. This  
experiment was repeated five times with similar results. (C) TC1 cells were 
injected s.c. into the flank of C57BL/6 mice. 14 d later, when the tumor 
was measurable, mice were immunized with a vaccine containing the 
HPV16 E749-57 peptide with 20 µg DOTAP and 25 µg LPS with or without  
IL-1 (2 µg on days 0, 1, 2, and 4). Each group contained 3–5 mice.  
P-values were calculated using the Mann-Whitney test. This experiment 
was repeated twice with similar results. **, P = 0.02; *, P = 0.03.
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American Peptide Co. APC-H-2Kb restricted SIINFEKL tetramer was ob-
tained from the National Institutes of Health Tetramer Core Facility. HIV 
envelope peptide RGPGRAFVTI and HPV E7 peptide RAHYNIVTF 
were obtained from the Polypeptide Group.
Tetramer staining. Lymph node or spleen cells (2–5 × 106) were incu-
bated for 30 min at 37°C in 0.2 ml of RPMI 1640 + 2% FCS containing 
50 µg/ml anti-FcR II (2.4G2) antibody with 2 µg/ml APC-conjugated 
H-2Kb SIINFEKL tetramer, followed by staining at 4°C for 30 min with PE 
Cy7 anti-CD8. Cells were washed in PBS with 0.1%BSA and analyzed with 
a BD LSRII, using FlowJo software (Tree Star).
Intracellular cytokine staining. Single-cell suspensions (1–5 × 106 cells/ml) 
from lymph nodes, spleen, liver, or lung were stimulated with ionomycin 
and phorbol 12-myristate 13-acetate (PMA), fixed, permeabilized, and stained 
as previously described (Ben-Sasson et al., 2009). For cytokine staining, cells 
were blocked with anti-FcR II (2.4G2; 50 µg/ml) for 5 min and stained for 
30 min at room temperature with anti-PerCP Cy5-5 anti-CD8 and eFluor 
450 anti–IFN-, PE anti–granzyme B. The stained cells were analyzed with 
a BD LSRII, using FlowJo software (Tree Star).
In vivo priming of adoptively transferred transgenic cells. Unless 
otherwise specified, cells (0.1–3 × 105) from lymph nodes of donor mice 
were injected i.p. or retroorbitally (RO) into normal recipients (3–5 mice for 
each experimental group). Mice were immunized s.c. by injection of 1 mg of 
OVA (Sigma–Aldrich) with 25 µg of LPS (Escherichia coli 0111:B4; InvivoGen). 
IL-1 was injected daily (2 µg/injection) s.c. for 5 d starting at 24 h after im-
munization, unless otherwise stated.
Preparation of single-cell suspensions from lymph nodes and spleen. 
Single-cell suspensions were prepared from the lymph nodes and spleens by 
mechanical dispersion of the organs with a syringe top over a 40-µm sieve 
on a 50-ml tube in RPMI 1640 containing 5% FCS.
Preparation of lymphocyte-enriched populations from liver and 
lung. The lymphocyte-enriched fraction was isolated from the liver by me-
chanical dispersion of the organ, followed by Percoll gradient centrifugation. 
In brief, the liver was cut into small pieces that were transferred to a 70-µm 
sieve on a 50-ml tube and pushed through the sieve with a syringe top. The 
cells were washed with RPMI 1640 containing 1% FCS, and the pellet was 
resuspended in 40% isotonic Percoll solution that was underlayed by 60% 
isotonic Percoll and spun at 2,000 RPM for 20 min at room temperature. 
Cells at the 40–60% Percoll interface were collected and washed with RPMI 
1640 containing 5% FCS. The pellet was resuspended in the same medium.
The lymphocyte-enriched fraction was isolated from the lung after di-
gestion with collagenase/DNase and further purification by Percoll gradient 
centrifugation. In brief, washed, perfused lung tissue was cut into small pieces 
and digested by incubation in Petri dishes for 30 min at 37°C in humidified 
CO2 incubator with collagenase/DNase (50 µg/ml collagenase-Liberase; 
Roche) and 8 U/ml DNase type I (Roche) in RPMI. The lung digest was 
then treated in the same manner as the liver fragments.
Monitoring donor CD8 transgenic cells. The percentage of donor cells 
among the single-cell suspensions of the lymph nodes, spleen, liver, and lung 
of the recipient mice was determined by staining for 30 min at 4°C with a 
cocktail of fluorochrome-conjugated anti-cell surface antibodies in the pres-
ence of 50 µg/ml of blocking anti-FcRII/III Abs (2.4G2), followed by flow 
cytometric analysis with a BD LSRII, using FlowJo software (Tree Star) for 
the identification of the OT-I–transferred cells. In C57BL/6 recipients, 
FITC-anti-V5, PE-anti-V2, and APC-anti-CD8 antibodies were used for 
the identification of the CD8+/V2+/V5+ OT-I cells. In GFP C57BL/6 
mice, the FITC conjugated antibody was omitted for the identification of the 
CD8+/V2+/GFP OT-I cells.
In CD45.1 C57BL/6 recipients, FITC-anti-CD45.1, PE-anti-V2, 
APC-anti-CD45.2, and PE-Cy7 anti-CD8 antibodies were used for the 
obtained in priming with heat killed Blastomyces dermatitidis 
(unpublished data).
The molecular mechanisms underlying IL-1 actions are 
still unresolved. IL-1 signals through the Myd88 pathway and 
has been reported to activate both NF-B and MAP kinases 
(Weber et al., 2010). This would allow both the expansion and 
differentiation processes that have been observed. Recently, 
it has been reported that IL-1–driven cytokine production by 
CD4 T cells is largely mediated through the activation of PI-3 
kinase and mTOR (Gulen et al., 2010; Chi, 2012). In addi-
tion, it has been shown that IL-33 signaling in CD8 T cells 
augments both the proliferative and the cytolytic activity 
of cells responding to vaccinia virus (Bonilla et al., 2012). 
Because IL-1 and IL-33 share IL-1RAcP as a co-receptor 
for signaling and activate similar, if not identical, pathways 
(Weber et al., 2010; Palmer and Gabay, 2011), it may well be 
that both molecules perform the same function in antigen-
stimulated CD8 cells, depending on expression of the appro-
priate cytokine receptor. Interestingly, the in vivo generalized 
expansion of antigen-stimulated CD4 cells is augmented by 
IL-1 but not by IL-33 (Ben-Sasson et al., 2009), possibly be-
cause of little or no expression of the IL-33 binding chain 
(T1-ST2) on naive CD4 T cells.
IL-1 displays properties that would seem to be of great 
value in enhancing primary responses and readiness to deal 
with reintroduction of pathogens. Thus, it strikingly enhances 
the magnitude of primary expansion, increases the degree of 
differentiation, allows the cells to enter tissues, and induces 
the capacity to develop an enhanced secondary response 
marked by increased responder cell expression of granzyme 
B and increased capacity to produce IFN-. The principal 
barrier to exploiting these extremely desirable properties is 
the potent proinflammatory effects of the cytokine. If a 
method could be found to tame IL-1 by limiting its range of 
action only to CD4 and/or CD8 cells or if a cell type–specific 
small molecule analogue could be identified, the possibility of 
exploiting the IL-1 adjuvant effect could be considered.
MATERIALS AND METHODS
Mice. Female mice of the following strains were obtained from Taconic 
Farms: TCR Tg OT-I/RAG1/ C57BL/6; TCR Tg OT-I/RAG1/ 
CD45.1 C57BL/6; TCR Tg OT-I/RAG1/ IL-1R1/ C57BL/6; TCR 
Tg OT-II/RAG1/ C57BL/6; TCR Tg OT-II/RAG1/ CD45.1 
C57BL/6; CD45.1 C57BL/6; RAG1/ C57BL/6; IL-1R1/ C57BL/6; 
and CD90.1 C57BL/6. UBC-GFP C57BL/6 and the appropriate C57BL/6 
control female mice were obtained from The Jackson Laboratory. WT 
BALB/c and C57BL/6 mice for the vaccinia and tumor experiments were 
obtained from Charles River. Mice were maintained under pathogen-free 
conditions and were used at 6–8 wk of age. Mice was cared for under proto-
cols approved by the NIAID Animal Care and Use Committee.
Cytokines, peptides, and antibodies. Recombinant mouse IL-1 was 
prepared as preciously described (Wingfield et al., 1986). Fluorochrome-
conjugated anti-V2 (B20.1) and anti-V5 (MR9–4) antibodies were pur-
chased from BD. Anti-CD45.1 (A20), anti-CD45.2 (104), anti-CD90.1 (HIS51), 
anti-CD90.2 (53–2.1), anti-CD4 (L3T4), anti-CD8 (53–6.7), anti–IFN- 
(XMG1.2), anti–granzyme B (16G.6) fluorochrome-conjugated antibodies 
were purchased from eBioscience. SIINFEKL peptide was purchased from 
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Cy5-5-anti-CD45.2, eFluor 450-anti-CD90.1, and PE Cy7-anti-CD90.2 
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determined by multiplying the cell number in the organ by the percentage 
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In vivo cytotoxicity assay. Target cell populations were prepared from naive 
B6 mice using RBC-lysed splenocytes. The residual white cells (2 × 107 
cells/ml PBS) were labeled with either 2.5 or 0.25 µM carboxyfluorescein 
succinimidyl ester (CFSE), (Molecular Probes) for 8 min at RT followed by 
quenching with 50% FCS for 2 min at RT. The CFSEhigh and CFSElow  
labeled cells were washed 3x with RPMI 1640 containing 10% FCS. The 
CFSEhigh target cells were pulsed with SIINFEKL peptide for 90 min at 37°C 
and the CFSElow cells were incubated under the same conditions as an inter-
nal control. The cells were mixed at a ratio of 2:1 CFSEhigh/CFSElow and in-
jected retroorbitally into mice. Lymph nodes and spleens were removed 18 h 
later and single-cell suspensions were analyzed for the percentage of CFSEhigh 
among total CFSE-labeled cells. A reduction to less than the starting percent-
age of 67% implies cytotoxicity of peptide-pulsed target cells.
Preparation of heat killed L. monocytogenes. L. monocytogenes (Lm) 
10403S was grown at 30°C overnight in BHI broth. Before infection, bacte-
ria were washed in Ringer’s lactate solution twice. Heat-killed L. monocyto-
genes (HKLM) were generated by heating the Listeria in Ringer’s lactate 
solution at 65°C for 30 min. All HKLM preparations were tested for residual 
bacterial viability by plating 100 µl of HKLM on BHI agar.
L. monocytogenes vaccination. Mice were inoculated via tail vein with 
either no bacteria (PBS), with 500 CFU of live L. monocytogenes, or equivalent 
of HKLM or with HKLM and IL-1 (10 µg which was delivered by 7-d mini-
osmotic pump as previously described [Ben-Sasson et al., 2009]). 29 d after 
priming, mice were challenged with 5 × 104 CFU of live L. monocytogenes, 
and then sacrificed 3 d after the challenge. Bacteria in liver were enumerated 
using serial dilution and colony counts on either BHI or TSA 5% blood agar 
plates. At least 5 mice were used in each experimental group.
Immunization with virus-expressed peptide and challenge with virus. 
BALB/c mice were immunized subcutaneously with 100 µg of the P18-I10 
(RGPGRAFVTI) peptide from the V3 loop of the IIIB strain of HIV-1 
(Takahashi et al., 1988) complexed in DOTAP liposomal transfection reagent 
(20 µg; Roche). Some mice were also given IL-1 (2 µg on days 0, 1, 2, and 4) 
or a single dose of 0.1 µg MALP2, 25 µg poly (I:C), and 2 µg CpG ODN 
1555 and 1466 on the day of the immunization (Zhu et al., 2010).
BALB/c mice were challenged i.p. with 2 × 107 pfu of recombinant 
vaccinia virus expressing gp160IIIB (vPE16; Earl et al., 1991). Mice were 
sacrificed 6 d after challenge; both ovaries were removed, homogenized in 
PBS, sonicated, and assayed for viral titers by culturing 10-fold serial dilutions 
with BS-C-1 cells. After 48 h of culture, crystal violet (0.1% in 20% Ethanol) 
was added to the cells and the number of plaques were counted and multi-
plied by the dilution factor.
TC1 tumor. The TC1 tumor cell line was derived from primary lung epi-
thelial cells of C57BL/6 mice that had been transfected with HPV 16 E6 and 
E7 genes (Feltkamp et al., 1993). 50,000 TC1 cells were injected subcutane-
ously into the right flank of 8-wk-old C57BL/6 mice. 14 d after tumor 
injection, some mice were immunized s.c. with 100 µg HPV E749-57 peptide 
(RAHYNIVTF; Feltkamp et al., 1993) with DOTAP alone or in combina-
tion with IL-1 (4 doses of 2 µg on day 0, 1, 2, and 4 after immunization). 
Tumor growth was measured every 2–3 d.
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